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Ketamine, a known antagonist of N-methyl-D-aspartic (NMDA) glutamate receptors, had
been used as an anesthetic particularly for pediatric or for cardiac patients. Unfortunately,
ketamine has become an abusive drug in many parts of the world while chronic and
prolonged usage led to damages of many organs including the brain. However, no
studies on possible damages in the brains induced by chronic ketamine abuse have been
documented in the human via neuroimaging. This paper described for the first time via
employing magnetic resonance imaging (MRI) the changes in ketamine addicts of 0.5–12
years and illustrated the possible brain regions susceptible to ketamine abuse. Twenty-one
ketamine addicts were recruited and the results showed that the lesions in the brains of
ketamine addicts were located in many regions which appeared 2–4 years after ketamine
addiction. Cortical atrophy was usually evident in the frontal, parietal or occipital cortices
of addicts. Such study confirmed that many brain regions in the human were susceptible
to chronic ketamine injury and presented a diffuse effect of ketamine on the brain which
might differ from other central nervous system (CNS) drugs, such as cocaine, heroin, and
methamphetamine.
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INTRODUCTION
Ketamine, a known antagonist of N-methyl-D-aspartic (NMDA)
glutamate receptors, had been used as an anesthetic, particu-
larly for pediatric or for cardiac patients. Ketamine employed in
prescribed medical conditions had its advantages as it did not
increase intracranial pressure during neurosurgery (Schmittner
et al., 2007) and had no postoperative neurological damage when
used in cardiopulmonary bypass patients (Smith et al., 2006).
Medically, ketamine has also been proposed for anticonvulsive
control (Dickenson and Ghandehari, 2007) and for controlling
injury after stroke via it action on the glycine, zinc, and magne-
sium components of the glutamate binding sites (Collins et al.,
1989); thus, protecting neuronal loss after stroke (Meldrum et al.,
1987) and preventing of the spread of depolarization after injury
(Hertle et al., 2012). This drug is, however, not without flaw.
Being one of the noncompetitive NMDA receptor antagonists like
phencyclidine and MK801, it would produce schizophrenia like
psychosis in human (Dickerson and Sharp, 2006). Unfortunately,
ketamine has now become an abusive drug in many parts of the
world and chronic and prolonged usage led to damages of many
organs in experimental animals (Yeung et al., 2009; Chan et al.,
2011; Tan et al., 2011a; Wai et al., 2012; Wong et al., 2012). The
damage on the nervous system included neuronal loss, synap-
tic changes, changes in functional magnetic resonance imaging
(fMRI) activities, and the formation of mutated tau protein in
neurons as described in models of rodents and monkeys (Yeung
et al., 2010a; Sun et al., 2011; Yu et al., 2012).
In the higher primate, chronic treatment of ketamine induced
changes of apoptotic markers in the prefrontal cortex and abnor-
mal behavior inmovement, walking, jumping, and climbing (Sun
et al., 2012). fMRI in monkeys also revealed hyperactivity in
entorhinal cortex, striatum regions, but hypoactivity in midbrain
and visual cortex (Yu et al., 2012). In the mice, prefrontal hip-
pocampal damages (Yeung et al., 2010a; Wai et al., 2013), pain
altercations, and schizophrenic like behavior (Becker et al., 2003,
2006) had been documented and GABA receptor and changes of
dopaminergic neurons were recorded in mouse model (Tan et al.,
2011b, 2012). In the human brain, so far, few studies appeared in
the literature. Our group, for example, revealed fMRI hypoactiv-
ities in the cerebellum of addicts (Chan et al., 2012). Narendran
et al. (2005) reported that ketamine addicts exhibited selective up-
regulation of dopamine D1 receptor via biochemistry. No study
was ever put forward summarizing human central nervous sys-
tem (CNS) lesions as yet. This paper described for the first time
via magnetic resonance imaging (MRI) changes in the addicts of
0.5–12 years of ketamine addiction, and demarcated the possible
brain regions susceptible to ketamine damages.
MATERIALS AND METHODS
SUBJECTS
This study had consents from patients and was approved by the
ethical committee of Sun Yat-sen University, Guang Zhou, China.
Twenty-one human ketamine addicts were employed in the study.
The ages of these patients were between 19 and 48 years old,
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with only two above 31 (one of 38 and another of 48). They all
had no previous medical history of brain trauma or neurological
diseases. The dosage used by the patients was from 0.2 to 3 g a
day but majority dosage was 1 g a day. Among them, 19 of these
patients took ketamine daily, while only two took it twice or three
times a week. The durations of drug addiction ranged from 0.5
to 12 years. The break down of addicts with three years addic-
tion or below was n = 6. Four to six years addiction was n = 7.
Seven years of addiction was n = 3 and over ten years of addic-
tion was n = 5. The patient data were indicated in Table1. The
brains of these patients were subjected to MRI image. Three age
matched normal subjects (ages 19, 21, and 40 years old) were used
as control for MRI imaging.
NEUROIMAGING STUDY
MRI was performed with a 3.0-Tesla imager (Achieva; Philips
Medical Systems, Best, the Netherlands). The images were
obtained with 5.0mm section thickness (ST). The field of view
(FOV) was 23 × 18 cm2 with 8 channel SENSE head coil. T1-
weighted images were obtained with 2000ms repetition time
(TR) and 20ms echo time (TE). T2-weighted images were
obtained with TR and TE at 3000ms and 20ms and fluid
attenuated inversion recovery (FLAIR) images were obtained at
11,000ms TR and 20ms TE. The total acquisition time for the
sequences was about 30min.
RESULTS
The results of lesions observed in all the 21 ketamine addicts
were depicted in Table 2. Those who had two or less regions in
the brain with lesions were classified as light damage. Those that
had three to four regions in the brain with lesions were classi-
fied as moderate damage, and those with five or more regions
with lesions were classified as severe damage. The MRI lesions
initially were observed as hyperintense spots (holes or patches) of
degeneration in the superficial white matter of the cortex which
appeared as early as 1 year after ketamine addiction (Figure 1A),
Table 1 | Characteristics of the ketamine addicts.
Years of No. of Dosage Frequency Drug
addiction addict manner
0.5 1 0.2 g Twice a week Nasal absorption
1 2 >0.5 g Every day or
three times a
week
Nasal absorption
2 1 >0.5 g Every day Nasal absorption
3 2 >0.5 g Every day Nasal absorption
4 2 ≥1g Every day Nasal absorption
5 2 ≥1g Every day Nasal absorption
6 3 ≥1g Every day Nasal absorption
7 3 ≥1g* Every day Nasal absorption
10 3 ≥1g Every day Nasal absorption
12 2 ≥1g Every day Nasal absorption
*One of three patients took 3g a day. The patient took ketamine along with
amphetamine and ecstasy. One patient took ketamine daily, another took
ketamine three times a week. Ta
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while each lesions spread to the internal capsule by 3 years
of addiction (Figure 1B). Slightly after, patches of hyperintense
degeneration spots appeared in the basal forebrain (Figure 2A),
cerebellum, and pons (Figure 2B), and diencephalon at 4 years
of addiction (Figure 2C). Likewise, diffusion blockage was
illustrated by FLAIR image in the parahippocampal gyrus and
insula, also by 4 years of addiction (Figure 3A), while atrophy of
the parahippocampal gyrus was observed a bit later by 5 years of
FIGURE 1 | Hyperintense spots (arrow) in superficial white matter and internal capsule of ketamine addicts. (A) FLAIR imaging of a 1 year ketamine
addict. (B) T2 imaging of a 3 years ketamine addict.
FIGURE 2 | MRI images of the brains of a 4 years ketamine addicts.
(A) T2 image of a horizontal brain section showing degenerative
hyperintense spots in basal forebrain (arrow). (B) T2 image of a
horizontal section showing hyperintense degeneration in cerebellum (a)
and in pons (b). (C) T2 image of a sagittal section showing
degeneration spots in diencephalon (thalamus).
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FIGURE 3 | FLAIR image of diffusion blockage as hyperintense spots in the parahippocampal gyrus (G) and insula (I) as well as atrophy of uncus
(arrow). (A) Ketamine addict of 4 years. (B) Ketamine addict of 5 years.
FIGURE 4 | T2 image showed parietal atrophy (arrow) in a sagittal
brain section of a ketamine addict of 4 years.
addiction (Figure 3B). Atrophy of the other parts of cortex was
first noted after 4 years of addiction, usually with atrophy on only
a small region of the cortex (Figure 4) and extended to two or
three regions (usually frontal, parietal, and occipital) of the cor-
tex by 7 years of addiction (Figure 5). Hyperintense lesions were
also observed in the corpus striatum by 6 years (Figure 6). In
this patient cohort, one patient had a combination of drugs and
was taking ketamine together with amphetamine and ecstasy. He
demonstrated early atrophy of cortex after taking the three drugs
together in 0.5 years, in which the basal prefrontal gyrus rectus
already exhibited significant atrophy (Figure 7A) when compared
with control (Figure7B). Similarly, cortical atrophy also occurred
FIGURE 5 | T2 image showed prefrontal and occipital atrophy (arrows)
in a sagittal brain section of a 7 years’ ketamine addict.
early in another patient who had used a high dose of ketamine,
in this case 3 g per day for 3 years (Figure 8). After 7 years of
addiction, in all other patients, lesions then appeared in the mid-
brain (Figure 9). From 10 to 12 years of addiction, all lesion sites
were as those described above.
Medical histories indicated that addicts over 4 year of ketamine
addiction displayedmemory deficits and anxiety depression while
those from the 5 to 7 years developed definitive ataxia and by 7
years and above, dyskinesia became obvious.
DISCUSSION
This study revealed the lesions in many regions of the brain of
ketamine addicts. These lesions appeared as minute patches in
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FIGURE 6 | T2 image showed hypertensive degenerative spots in
corpus striatum (arrows) of a 6 years’ ketamine addicts.
FIGURE 7 | T1 images showed atrophic basal prefrontal (gyrus rectus)
lesion of a 0.5 years ketamine addicts who took three drugs including
ketamine (A). (B) Control with no retraction of gyrus rectus (arrow).
the first year and became larger sites of atrophy by 4 years of
addiction. The majority of the addicts was on dosage of 1 g per
day and used ketamine daily for several years. In this work, since
the volunteers were mostly below 30 years old and only 2 indi-
viduals above 30 years old, a comparison of the effect of age
upon addiction was not conclusive in this stage, even though
we had seen no worse in the aged group (above 30 years old)
when compared with the slightly younger old. A study of age
response would definitely be conducted in future. However, it is
well-known that ketamine addicts were usually young as repre-
sented in this cohort. The brain regions affected were prefrontal,
parietal, occipital, limbic, brainstem, and corpus striatum. The
lesions affected both the gray and white matter, i.e., neurons and
nerve fibers in the human; these were similar to those reported
earlier by us in the mice and the monkey (Yu et al., 2012). This
FIGURE 8 | T2 image showed significant prefrontal atrophy (arrow) in a
horizontal brain section of a ketamine addict who had high dose of
ketamine (3g per day) for only 3 years.
FIGURE 9 | T2 image of a coronal section that showed degenerative
lesion (arrow) in the brainstem (midbrain) of a ketamine addict of 7
years.
MRI study also collated with the work by Morgan and Curran
suggesting a loss of memory via psychological examination in
chronic ketamine abuses (Morgan and Curran, 2006). In animals,
prefrontal cortex apoptosis, mutated tau aggregation, brainstem
chemical changes, and cerebellar apoptosis had been reported
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(Mak et al., 2010; Yeung et al., 2010b; Sun et al., 2011, 2012;
Tan et al., 2011b, 2012; Yu et al., 2012; Wai et al., 2013). In
fact, in the mice model, it had been documented both neurons
and fibers (white matter) were both targets like in this report
consisting of human subjects (Mak et al., 2010; Yeung et al.,
2010b). Along with structural changes, fMRI and functional stud-
ies confirmed functional and cognitive derangements (Morgan
and Curran, 2006; Sun et al., 2011, 2012; Chan et al., 2012; Yu
et al., 2012). This human MRI brain imaging on the ketamine
addicts thus consolidated that the areas of lesion in mice, mon-
key, and human were essentially similar. We now have clear and
unequivocal proof of damages in the CNS upon chronic use
of ketamine in human. As for the combination of drugs, we
had only one individual on three types of drug—amphetamine,
ecstasy and ketamine. The individual was only on such drugs
for half a year with low dosage of ketamine, but his lesions were
more vigorous than the addicts who had been on the drug for 3
years. This preliminary observation suggested severe detrimental
effects on brain upon the combination of abusive drugs in the
addicts.
Hyperdensity spots in computerized axial tomography (CAT)
scan usually pointed to demyelination or metabolic changes
(Brismar and Ozand, 1994; Matsushima et al., 1997). For MRI,
while hyperintensive spot in T1 imaging pointed to toxicity or
metabolic lesion, T2 hyperintensive could refer to demyelination
and hardening of arteries (Hyttinen et al., 2009). Other stud-
ies on T1, T2, and FLAIR MRI indicated even more possibilities
for hyperintensive spotty or non-spotty lesions (Cakirer et al.,
2003). For instance, T1 hyperintensity could be related to infarct,
infection, axonal damage, hemorrhage or vascular change and
neoplasm (Cakirer et al., 2003), T2 hyperintensite image might
indicate cytotoxicity, vasogenic edema whilst metabolic toxicity,
encephalopathy, vasogenic edema would restrict diffusion and
contributed to FLAIR hyperintensity (Cakirer et al., 2003). In our
patients, these lesions observed were probably related to cytotox-
icity, axonal damage, and vasogenic edema which we indicated as
“degeneration” while atrophy of cortex was the last sequel of the
events.
There were some studies on the neuroimaging of addicts using
different drugs. Reneman et al. (2006), for example, using pro-
ton magnetic resonance spectroscopy (1H-MRS) suggested the
cortical and subcortical reduction of serotonin transporter in
ecstasy patients. Also using magnetic resonance spectroscopy, de
Win et al. (2008a) reported thalamic damage by ecstasy. Apart
from the thalamus, other subcortical structures in the globus
pallidus and putamen were also affected by esctacy (de Win et al.,
2008b). Using simple MRI and diffusion tensor imaging (DTI)
techniques, other areas of the brain were reported to be dam-
aged by ecstasy, e.g., the limbic cortex (Thompson et al., 2004),
the medial temporal cortex (Thompson et al., 2004), callosum
(Salo et al., 2009), limbic system (Sowell et al., 2010), and hip-
pocampus (DenHollander et al., 2012). Front-cortical and striatal
damages were featured in the cocaine treated rat by MRI (Gozzi
et al., 2011), callosum damage by DTI in human cocaine addicts
(Moeller et al., 2007) and damage in frontal white matter in
prenatally cocaine exposed human addicts (Smith et al., 2001).
In the heroin addicts, for example, decreased gray matter was
observed in the frontal, cingulate, and occipital cortices (Wang
et al., 2012). In the cocaine addicts, cue-induced cocaine crow-
ing involved the left dorsolateral frontal cortex and the anterior
cingulate (Bolla et al., 1998; Maas et al., 1998; Wexler et al., 2001;
Goldstein et al., 2004). These areas were also found to be involved
in methamphetamine craving (Yin et al., 2012). Toda revisited
these damaged areas in a review and proposed that these areas
had glutamatergic projections to the nucleus accumbens (Toda,
2012). In this study, the ketamine damaged regions in the human
subjects were put forward for the first time and resolved that
they included diffusely many regions: frontal, parietal, occipital
cortices, parahippocampal gyrus, striatum (including caudate),
cerebellum, and brainstem. However, no obvious involvement
was observed in the cingulate gyrus. Some of these areas were
the same as cocaine and ecstasy patient, e.g., frontal, striatum,
and limbic. However, ketamine presented a rather diffuse effect in
many other of areas of the brain which might differ from cocaine,
heroin, or methamphetamine.
This piece of work further suggests that addicts even on
a single drug alone like ketamine might lead to atrophy of
the brain after a few years of addiction. As addicts usually
take ketamine at different time and ad lib, it was very diffi-
cult to compare dosages. In this work, there were hints that
increasing dosage or combination of ketamine with other abu-
sive drug would hasten the damages. It is important therefore
to compare the years of duration and with a certain level of
dosage which at least led some usable data. Further work should
emphasize on the comparison of the interaction of these abuse
drugs.
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